All In Biotech

Drug Trial Radar · NCT06568939

A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

A Phase 2, Open-Label, Randomized, Global Study of Three Telisotuzumab Vedotin Regimens in Subjects With Previously Treated c-Met Overexpressing, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer

Last checked: Nov 20, 2026Latest source record: Oct 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 150 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

150

Planned (sponsor's estimate)

Start

Jan 20, 2025

Primary completion

Feb 2028

Study completion Feb 2028

Sponsor

Lead sponsor
AbbVieAbbVie (ABBV)
Sponsor type
Industry
First posted
Aug 23, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-small cell lung cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung. The purpose of this study is to assess how safe telisotuzumab vedotin is in adult participants with NSCLC. Change in disease activity and adverse events will be assessed. Telisotuzumab vedotin is an investigational drug being developed for the treatment of NSCLC. Participants will be randomly assigned a treatment of telisotuzumab vedotin in 1 of 3 arms at an 1:1:1 ratio. Each group receives intravenous (IV) infusion of telisotuzumab vedotin at different doses. Approximately 150 adult participants with c-Met overexpressing NSCLC will be enrolled in the study at approximately 80 to 90 sites worldwide. Participants will receive IV telisotuzumab vedotin at 1 of 3 dose regimens as part of a 3 year study duration. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

Conditions

  • Non-Small Cell Lung Cancer
  • c-MET

Interventions

  • Telisotuzumab VedotinDrug

    Intravenous (IV) Infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants with Treatment-Emergent Adverse Events (AE)s (Any-grade and Grade >= 2)Time frame: Up to Approximately 3 Years
  2. Percentage of Participants with Treatment-Emergent Interstitial Lung Disease (ILD)Time frame: Up to Approximately 3 Years
  3. Percentage of Participants with Treatment-Emergent Peripheral NeuropathyTime frame: Up to Approximately 3 Years
  4. Percentage of Participants with Treatment-Emergent Ocular Surface DisordersTime frame: Up to Approximately 3 Years
  5. Percentage of Participants with Treatment-Emergent AEs Leading to Study Drug DiscontinuationTime frame: Up to Approximately 3 Years
  6. Percentage of Participants with Grade 5 Treatment-Emergent AEsTime frame: Up to Approximately 3 Years
  7. Objective Response (OR) by Blinded Independent Central Review (BICR)Time frame: Up to Approximately 3 Years

Locations

83 sites in 7 countries. Site status is shown where the registry gives one.

  • Ironwood Cancer and Research Center /ID# 276370

    Chandler, Arizona · Recruiting

  • University of Arkansas for Medical Sciences /ID# 272923

    Little Rock, Arkansas · Recruiting

  • Start Los Angeles /ID# 284999

    Los Angeles, California · Recruiting

  • Valkyrie Clinical Trials /ID# 271322

    Los Angeles, California · Recruiting

  • FOMAT Medical Research - Clinica mi Salud by Focil Med /ID# 284816

    Oxnard, California · Recruiting

  • Yale New Haven Hospital /ID# 271584

    New Haven, Connecticut · Completed

  • Cancer Specialists of North Florida - Jacksonville - AC Skinner Parkway /ID# 270899

    Jacksonville, Florida · Recruiting

  • Ocala Oncology Center /ID# 273697

    Ocala, Florida · Recruiting

  • Memorial Hospital West /ID# 270313

    Pembroke Pines, Florida · Recruiting

  • Comprehensive Hematology Oncology /ID# 270422

    St. Petersburg, Florida · Recruiting

  • Florida Cancer Specialists - North /ID# 271995

    St. Petersburg, Florida · Recruiting

  • Florida Cancer Specialists - East /ID# 271993

    West Palm Beach, Florida · Recruiting

  • University Cancer and Blood Center /ID# 270969

    Athens, Georgia · Recruiting

  • Northwest Georgia Oncology Centers /ID# 275374

    Marietta, Georgia · Recruiting

  • Memorial University Medical Center /ID# 272467

    Savannah, Georgia · Completed

  • Kaiser Permanente Moanalua Medical Center /ID# 272916

    Honolulu, Hawaii · Recruiting

  • University of Illinois Hospital and Health Sciences System /ID# 275345

    Chicago, Illinois · Recruiting

  • Illinois Cancer Specialists /ID# 274678

    Niles, Illinois · Recruiting

  • OSF St. Francis Medical Center /ID# 281591

    Peoria, Illinois · Recruiting

  • Springfield Clinic - First /ID# 272576

    Springfield, Illinois · Recruiting

  • Nebraska Hematology-Oncology /ID# 272970

    Lincoln, Nebraska · Recruiting

  • Nebraska Cancer Specialists - Omaha - Wright Street /ID# 271527

    Omaha, Nebraska · Recruiting

  • Renown Regional Medical Center /ID# 273535

    Reno, Nevada · Recruiting

  • Astera Cancer Care /ID# 272359

    East Brunswick, New Jersey · Recruiting

  • Regional Cancer Care Associates /ID# 270783

    Teaneck, New Jersey · Recruiting

  • Montefiore Medical Center - Einstein Campus /ID# 277169

    The Bronx, New York · Recruiting

  • Clinical Research Alliance (SMO/Network/Consortium) /ID# 270455

    Westbury, New York · Recruiting

  • FirstHealth of the Carolinas- Speciality Center /ID# 272924

    Pinehurst, North Carolina · Recruiting

  • Mercy Health - Perrysburg Cancer Center /ID# 270536

    Perrysburg, Ohio · Recruiting

  • Genesis Healthcare System /ID# 273361

    Zanesville, Ohio · Recruiting

  • Guthrie Robert Packer Hospital /ID# 270316

    Sayre, Pennsylvania · Recruiting

  • Cancer Care Associates Of York /ID# 270971

    York, Pennsylvania · Recruiting

  • Medical University of South Carolina /ID# 273272

    Charleston, South Carolina · Recruiting

  • Saint Francis Cancer Center - Greenville /ID# 276368

    Greenville, South Carolina · Recruiting

  • SCRI Oncology Partners /ID# 270162

    Nashville, Tennessee · Recruiting

  • Texas Oncology - Dallas - Worth Street /ID# 278947

    Dallas, Texas · Recruiting

  • Texas Oncology - Northeast Texas /ID# 272000

    Tyler, Texas · Recruiting

  • Community Cancer Trials Of Utah /ID# 276598

    Ogden, Utah · Recruiting

  • Virginia Cancer Specialists - Fairfax /ID# 272004

    Fairfax, Virginia · Recruiting

  • Medical Oncology Associates - Spokane /ID# 277172

    Spokane, Washington · Recruiting

Showing 40 of 83 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.